The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

被引：0
|
作者：
Stadler, W. M.
Figlin, R. A.
Ernstoff, M. S.
Curti, B.
Pendergrass, K.
Srinivas, S.
Canfield, V.
Weissman, C.
Poulin-Costello, M.
Bukowski, R. M.
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] City Hope Comprehens Canc Ctr, Los Angeles, CA USA
[3] Dartmouth Med Sch, Lebanon, NH USA
[4] Providence Portland Med Ctr, Portland, OR USA
[5] Kansas City Canc Ctr, Overland Pk, KS USA
[6] Stanford Univ Hosp, Stanford, CA 94305 USA
[7] Canc Care Associates, Oklahoma City, OK USA
[8] New York Oncol Hematol, Latham, NY USA
[9] Bayer HealthCare, West Haven, CT USA
[10] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5036
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Targeted therapies for non-clear renal cell carcinoma
    Singer, Eric A.
    Bratslavsky, Gennady
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    TARGETED ONCOLOGY, 2010, 5 (02) : 119 - 129
  • [42] The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma
    Naik, Priyanka
    Dudipala, Harshitha
    Chen, Yu-Wei
    Rose, Brent
    Bagrodia, Aditya
    Mckay, Rana R.
    THERAPEUTIC ADVANCES IN UROLOGY, 2024, 16
  • [43] Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
    Tykodi, Scott S.
    Gordan, Lucio N.
    Alter, Robert S.
    Arrowsmith, Edward
    Harrison, Michael Roger
    Percent, Ivor John
    Singal, Rakesh
    Van Veldhuizen, Peter J.
    George, Daniel J.
    Hutson, Thomas E.
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Kalebasty, Arash Rezazadeh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [44] Non-Clear Cell Renal Cell Carcinoma, Part 1: Histology
    Valenca, Loana B.
    Hirsch, Michelle S.
    Choueiri, Toni K.
    Harshman, Lauren C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 308 - 313
  • [45] Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options
    Ahrens, Marit
    Scheich, Sebastian
    Hartmann, Arndt
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 128 - 135
  • [46] Non-Clear Cell Renal Cell Carcinoma, Part 2: Therapy
    Valenca, Loana B.
    Hirsch, Michelle S.
    Choueiri, Toni K.
    Harshman, Lauren C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (06) : 383 - 391
  • [47] Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
    Sepe, Pierangela
    Ottini, Arianna
    Pircher, Chiara Carlotta
    Franza, Andrea
    Claps, Melanie
    Guadalupi, Valentina
    Verzoni, Elena
    Procopio, Giuseppe
    CANCERS, 2021, 13 (15)
  • [48] Targeted therapies and the treatment of non-clear cell renal cell carcinoma
    Bellmunt, J.
    Dutcher, J.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1730 - 1740
  • [49] Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).
    Gulati, Shuchi
    Tangen, Catherine
    Ryan, Christopher W.
    Vaishampayan, Ulka N.
    Shuch, Brian M.
    Barata, Pedro C.
    Pruthi, Deepak K.
    Bergerot, Cristiane Decat
    Tripathi, Abhishek
    Thompson, Ian M.
    Lara, Primo N.
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Does immunoscore have a significant effect on survival for non-clear cell renal cell carcinoma as well as clear cell renal cell carcinoma?
    Ismail Selvi
    Umut Demirci
    Nazan Bozdogan
    Halil Basar
    International Urology and Nephrology, 2021, 53 : 1135 - 1138
12345